Test Price
2,800 AED✅ Home Collection Available
POT1 Gene Melanoma Susceptibility Test (Familial Type 10) – NGS in UAE | 2800 AED | DHA-Licensed Genetic Screening
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity: Next‑generation sequencing of the POT1 gene achieves 99.9% analytic sensitivity and specificity across all coding exons and intron‑exon boundaries, certified under ISO 9001:2015.
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection: Available daily from 8 AM to 11 PM. A licensed phlebotomist visits your residence or workplace using sterile, temperature‑regulated transport for whole blood or dried blood spot (FTA card) collection.
Post‑Test Tele‑Guidance: Every report is accompanied by a one‑on‑one telephonic consultation with a DHA‑licensed Consultant Medical Geneticist to explain variant classifications, risk implications, and recommended surveillance intervals.
Insurance Verification: Direct pre‑test insurance coverage check via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The POT1 Gene Susceptibility Test (Familial Type 10) employs Next‑Generation Sequencing (NGS) on an Illumina platform to detect germline mutations in the POT1 gene, which encodes the protection of telomeres protein 1. Pathogenic variants in POT1 are associated with hereditary cutaneous malignant melanoma type 10 (OMIM #615134), conferring a markedly elevated lifetime risk of melanoma. This analysis is recommended for individuals with a strong family history of melanoma, multiple primary melanomas, or early‑onset disease (before age 40). The test covers the full coding region plus intron‑exon boundaries, ensuring detection of both known familial variants and novel mutations.
| Feature | Our Test (POT1 NGS) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Precision | 99.9% analytic sensitivity & specificity; complete coding exons + intron‑exon boundaries | Limited to known familial variants; misses novel or rare mutations |
| Methodology | NGS (Next‑Generation Sequencing) on Illumina platform | Sanger sequencing of single exons |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
Physician Insight & Safety Protocols
“A positive POT1 result is not a diagnosis of melanoma; it indicates an inherited predisposition that warrants intensified dermatological surveillance and family risk counselling. Every result must be interpreted within the full context of personal and family history. Our post‑test tele‑guidance ensures you understand the implications and can take empowered, evidence‑based next steps.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Important Advisory
Do not discontinue any prescribed medications without consulting your treating physician. This genetic test is a risk‑assessment tool and does not replace regular clinical or dermatological examinations. Always follow your healthcare provider’s recommendations for skin checks and sun protection.
🚨 Safety Exclusion Criteria & ER Red Flags
Exclusion Criteria & Emergency Indicators
- Exclusion Criteria: Patients unable to provide informed consent after genetic counselling; minors without legally authorised guardian consent per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability; individuals who have received an allogeneic bone marrow transplant (may interfere with germline DNA analysis).
- Emergency Red Flags (seek immediate care): Rapidly changing mole, new atypical lesion, or melanoma symptoms such as itching or bleeding while awaiting results. Genetic counselling does not replace urgent dermatological evaluation.
Patient FAQ & Clinical Guidance
1. What is the POT1 gene and why should I be tested?
Snippet: The POT1 gene test identifies inherited mutations that dramatically raise lifetime melanoma risk, guiding personalised, life‑saving screening plans for you and your relatives.
Testing is recommended if you have a strong family history of melanoma, multiple primary melanomas, or early‑onset disease. Your oncology team will use the result to tailor dermatological check‑ups and consider preventive measures such as full‑body photography and mole mapping.
2. What does the test involve and how is the sample collected?
Snippet: A simple home blood draw or a few dried blood spots on an FTA card are used to extract DNA for next‑generation sequencing in our DHA‑licensed facility.
Our phlebotomist arrives at your home between 8 AM and 11 PM in a temperature‑controlled vehicle. For infants or difficult veins, a single drop of blood on an FTA card is sufficient. No special fasting is required; you must complete a genetic counselling session to document your family pedigree and provide informed consent before sample collection.
3. How long do results take and will a doctor interpret them for me?
Snippet: Results are reported within 3–4 weeks, and every report is explained by a DHA‑licensed Consultant Medical Geneticist during a dedicated telephonic post‑test consultation.
You will receive a secure digital report listing the variant classification (pathogenic, likely pathogenic, uncertain significance, likely benign, or benign). The included tele‑guidance session covers risk interpretation, recommended screening intervals, and implications for family members who may benefit from cascade testing.
UAE Regulatory & Data Privacy Adherence
This genetic testing service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed exclusively within the UAE. Informed consent and mandatory genetic counselling are conducted prior to testing, upholding the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory is accredited under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | POT1 Gene Melanoma Susceptibility Test (Familial Type 10) – NGS |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Dried Blood Spots (FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina Platform |
| ICD-10-CM Code | Z15.09 (Genetic susceptibility to other malignant neoplasm) |
| LOINC Code | 93931-7 (Hereditary cutaneous malignant melanoma susceptibility gene panel) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians